APA (7th ed.) Citation

J, S., L, Y., C, S., KG, M., AJ, C., ER, R., . . . OA, C. (2024). Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 146, 107161. https://doi.org/10.1016/j.ijid.2024.107161

Chicago Style (17th ed.) Citation

J, Stemler, et al. "Immunogenicity, Reactogenicity, and Safety of a Second Booster with BNT162b2 or Full-dose MRNA-1273: A Randomized VACCELERATE Trial in Adults Aged ≥75 Years (EU-COVAT-1-AGED Part B)." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 146 (2024): 107161. https://doi.org/10.1016/j.ijid.2024.107161.

MLA (9th ed.) Citation

J, Stemler, et al. "Immunogenicity, Reactogenicity, and Safety of a Second Booster with BNT162b2 or Full-dose MRNA-1273: A Randomized VACCELERATE Trial in Adults Aged ≥75 Years (EU-COVAT-1-AGED Part B)." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 146, 2024, p. 107161, https://doi.org/10.1016/j.ijid.2024.107161.